Medicines Formulary

Medicines A–Z

R

Drug name	NICE TAs	Comments
Ravulizumab (Ultomiris®)	TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
Reflectant (Dundee) sunscreens		Unlicensed specials
Regadenosan
Regorafenib (Stivarga®)	TA488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours TA514 - Regorafenib for previously treated advanced hepatocellular carcinoma TA556 - Regorafenib for previously treated advanced hepatocellular carcinoma TA866 - Regorafenib for previously treated metastatic colorectal cancer	For hospital use only
Relugolix/Estradiol/Norethisterone (Ryeqo®)		Ryeqo ESCA (PDF)
Remifentanil injection
Renavit		Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis.
Repaglinide tablets
Repevax		Supported with PGD
Resilizumab (Cinqaero®)	TA479 - Raslizumab for treating severe eosinophilic asthma	Hospital only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.